Clinical Trial Search

Primary: Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12 — 6.7; 6.9; -2.6; -2.6 Units on a scale

Primary: Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline — -0.15; -54; -1; -81.5 mg/dl

Primary: The Time to Sputum Culture Conversion at Week 8 (Stage 1) — 51; NA Days — p=0.0034

Primary: Progression Free Survival (PFS) Rate at 12 Months — 21.2; 25.8 percentage of participants

Primary: Post-baseline Changes Compared to Placebo (at 1-, 2-, and 3-hours Post Infusion Initiation [ie, at the End of 5, 15 and 30 ng/kg/Min Infusions]) in Cardiac Index (CI)…

Primary: Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. — 46; 50 participants — p=<0.05

Primary: Number of Participants With Virological Response (Viral Load Less Than 50 Copies/mL) at Week 24 - Time to Loss of Virologic Response (TLOVR) — 13 Participants

Primary: Response to Induction Chemotherapy (CR or PR) — 81.2 percentage of participants

Primary: Phase I: Determination of the Maximum Tolerated Dose (MTD) — 400 mg

Primary: Sum of Pain Intensity Differences (SPID 24) — -51.23; 25.46 units on a scale

Primary: 6 Month Progression Free Survival (PFS) — 9.4 percentage of patients

Primary: Maximum Tolerated Dose (MTD) of JI-101 — 400 mg

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease. — 26.7; 28.5; 28.6; 27.9 titers

Primary: Change in Blood Concentrations — 4.2; -0.03 ng/ml

Primary: Illicit Opioid Use as Determine by Urine Dipsticks — 13.64; 32.56 % of urines positive for opioids — p=0.035